Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

November 4, 2026

NASDAQ US Health Care Biotechnology earnings 72 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us on today's call. The slide deck that goes with this webcast is available in the Investors and Media area of our site, cytokinetics.com, and today's press release is there as well. Robert Blum, our President and Chief Executive Officer, will start us off with a review of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will talk about the commercial launch of MYQORZO in the U.S. and Europe. Fady Malik, EVP of R&D, will share updates on aficamten. Steve Heitner, SVP and Chief Medical Officer, will give updates on our ongoing clinical development programs. Sung Lee, EVP and Chief Financial Officer, will walk through the financials for the quarter. And last, Robert will offer closing remarks. As this slide shows, forward-looking statements will be part of today's discussion, and those carry risks and uncertainties. Our SEC filings describe these factors, so please refer to them. I'll now hand the call over to Robert.

Robert I. Blum

executive
#2

Thanks, Diane, and thank you everyone for being on today's call. For Cytokinetics, the third quarter marked yet another stretch of solid execution as we keep building a leading specialty cardiology company centered on muscle; during Q3, we advanced on every priority that underpins that strategy. With almost 9 months now behind us, MYQORZO's launch keeps surpassing what we expected. MYQORZO brought in $44.5 million of net revenue during the third quarter, which is 76% higher than Q2. As Andrew will explain, we saw growth in the count of prescribers, in prescribing per physician, and in patients dispensed. These trends, in our view, mirror MYQORZO's differentiated profile, and we believe there is considerable room for further growth. Beyond the United States, our German launch has gotten off to a robust start, and we keep securing approvals in further geographies, most recently including Canada and the United Kingdom. Our expectation is to launch in the U.K. during this quarter and in other countries in 2027. We're also eager for the PDUFA date tied to MAPLE-HCM data, which falls on November 14. Beyond oHCM, we are working hard to reach more HCM patients with aficamten; in August, we shared the complete ACACIA-HCM results in a hotline session at ESC alongside simultaneous publication in the New England Journal of Medicine; indeed, that presentation formed part of ESC's opening plenary session, a clear signal of the cardiology community's enthusiasm, given that today no approved therapy exists that targets the underlying disease for nHCM. At ESC we further presented extra findings from prespecified analyses of ACACIA-HCM that reinforce aficamten's potential in nHCM; those findings move us nearer to possible commercial availability of a treatment covering the full spectrum of symptomatic HCM patients. With these results in hand, we remain on track to file a supplemental NDA with FDA during this quarter and an application with the EMA in early 2027. Meanwhile, subject to regulatory approval, we are getting ready for a potential nHCM launch, drawing on the commercial foundation built with MYQORZO in oHCM. Andrew will say more about our commercial readiness shortly. Beyond aficamten, we kept moving our pipeline forward over the quarter. Our later-stage trials of omecamtiv mecarbil and ulacamten keep progressing. And earlier in the pipeline, we hit a preclinical milestone in our Accutar collaboration, which centers on targeted protein degraders aimed at muscle-related diseases. All told, our third quarter results show the progress we are making toward our Vision 2030. Going forward, our priorities are plain: file the sNDA in nHCM, get ready for a potential nHCM launch, extend MYQORZO into further geographies and, importantly, sustain our commercial momentum in oHCM while pushing our pipeline ahead, all while remaining disciplined in how we deploy capital. With that, I'll hand the call to Andrew, please.

Andrew Callos

executive
#3

Thank you, Robert. MYQORZO posted strong growth again this quarter, and the launch is still beating our expectations. In Q3, we're glad to see gains in prescribing, patient demand and market access, and the CMI category itself kept expanding; these trends indicate MYQORZO is on a solid trajectory in its first year, and we're focused on carrying that momentum into 2027. As promised at launch, we keep tracking performance through 3 key metrics: breadth of prescribing, depth of prescribing and patient volume. During the third quarter, all 3 grew, powered by a widening prescriber base. By the close of Q3, close to 1,100 unique health care providers across the U.S. had written for MYQORZO, versus more than 700 when Q2 ended. These HCPs have on average written MYQORZO for nearly 4 of their patients, versus 3 in the prior quarter. For high-volume CMI writers, that number stands at 7 patients, versus 5 in Q2; we think this rise in prescribing shows physicians gaining confidence in MYQORZO. On patient demand, by the end of Q3, more than 2,800 patients had received MYQORZO, roughly 86% above the 1,500 at the close of Q2. Although syndicated data has limits, our internal analysis indicates new-to-brand exit share for MYQORZO within CMI keeps climbing, nearing 45% in Q3, versus approximately 40% in Q2. Our launch approach centered on high-volume CMI prescribers, and our NBRx share is highest among these HCPs at close to 50%, an early signal of future growth. We stay committed to reaching greater than 50% new-to-brand exit share by year-end, which would be a strong outcome for the second entrant within under a year of launch. Besides capturing new-to-brand share, MYQORZO is also helping the CMI category expand. Q3 '26 versus Q3 '25 new-to-brand prescription grew 56%. Comparing year-to-date growth with the same period in '25, the CMI market has grown 45% since MYQORZO arrived, and significant room to grow remains. Of approximately 120,000 eligible oHCM patients in the U.S., only about 28,000 are treated with the CMI today. That leaves over 75% of CMI-eligible patients who could benefit from therapy, and that's where our launch remains focused. As we've said, before launch, prescribing was concentrated among high-volume CMI prescribers who historically made up approximately 80% of CMI volume. By the end of Q3, our sales team had reached more than 95% of these HCPs. Since launch, as we keep growing share among high-volume prescribers, adoption has also widened past this core group. Specifically, low-volume CMI prescribers now make up 30% of all MYQORZO prescribers, while prescribers naive to CMI account for another 35%. Importantly, in Q3, we estimate the CMI naive prescriber segment represented approximately 70% of total CMI growth since Q2. Access keeps widening: we closed the third quarter with commercial coverage above 60% of lives, compared with 50% at the close of Q2, and we held Medicare coverage steady across 2026. During Q3, more than 80% of prescriptions were paid, which shows continued progress on access and on how well we handle the payer appeal process. In Germany, our launch keeps building momentum. MYQORZO had already won more than 50% of new CMI patient starts by the end of August. Canada has just granted us approval, and we anticipate launching in the U.K. during this quarter, with more countries following in 2027. Consequently, we anticipate that MYQORZO will be on the market across every major European country in 2027. Meanwhile, with our planned sNDA submission for nHCM coming this quarter, we are getting ready for a possible commercial launch in that indication in 2027. Our field force was built from day one to call on the physicians treating both obstructive and nonobstructive patients, so that infrastructure already exists. We are likewise developing disease awareness to support branded education, and our payer account teams are getting set to engage payers through compliant pre-approval information exchange ahead of coverage discussions. In the U.S., we estimate more than 200,000 patients have received an nHCM diagnosis, and more than 120,000 of them are symptomatic and eligible for treatment. New market research responding to ACACIA-HCM indicates that, should MYQORZO win approval for symptomatic nHCM patients, physicians foresee a meaningful role for the therapy, especially among those with heavier symptom burden or ongoing functional limitations, where unmet need is greatest. Notably, physicians said patients carrying the heaviest symptom burden could be the ones most likely to be treated, which may push utilization higher in that segment. Beyond that, a dual indication label might further reinforce MYQORZO's standing in oHCM as physicians build wider experience and confidence with MYQORZO in both obstructive and nonobstructive HCM. In the end, we hope MYQORZO gains approval to serve this significant unmet need. On the whole, we are highly encouraged by how our launch markets are performing. It speaks to MYQORZO's differentiated profile and to the execution of our colleagues throughout the U.S. and Europe. Taken together, this progress is laying a strong foundation for continued growth. With that, I'll hand the call to Fady.

Fady Malik

executive
#4

Thanks, Andrew. For further distinguishing aficamten's clinical profile, the third quarter was a key stretch. Back in August, at a hotline session during the European Society of Cardiology, we laid out the complete findings from ACACIA-HCM — our pivotal Phase III clinical trial of aficamten in patients who have symptomatic nHCM. Simultaneously, those findings appeared in the New England Journal of Medicine. As we reported before, on both dual primary endpoints aficamten hit statistically significant improvements compared with placebo — in patient-reported health status as measured by KCCQ and in exercise capacity as measured by peak VO2. Aficamten additionally reached significance on 3 of 5 key secondary endpoints, NYHA class and NT-proBNP among them. Importantly, the treatment effect held consistently across every prespecified subgroup, including patients taking beta blockers, those with intracavitary obstruction, and both genotype positive and genotype negative patients. Cardiology community reaction at ESC was quite favorable. HCM experts of the highest standing described the results as a transformative moment for people living with nonobstructive HCM — a population that right now has no approved treatments. Since ESC, we've seen strong engagement from the HCM community, including centers of excellence, patient advocacy groups, and physicians treating these patients every day; with no approved therapies that address the underlying disease in nHCM, we believe these results have the potential to meaningfully change how HCM is treated. We also presented additional ACACIA-HCM analyses at ESC and HFSA that further characterize aficamten's treatment effect and safety in nHCM. At ESC, our data showed aficamten significantly improved diastolic function — meaning how well the heart relaxes and fills — and reduced left ventricular wall thickness, with these effects strengthening as treatment continues. These findings related to aficamten's mechanism help clarify the underlying effects on the heart that produce improvements in symptoms and exercise capacity. At the Heart Failure Society of America meeting in October, we presented data showing that aficamten improved global exercise performance across multiple domains of the cardiopulmonary exercise test in addition to peak VO2. In a second presentation, a responder analysis, 53% of patients on aficamten achieved a clinical meaningful response in 3 or more domains compared with 13% on placebo, which puts the mean treatment effect in the clinical context. With respect to safety, an ACACIA-HCM analysis showed that heart failure events occurred early during titration, often following a triggering event such as atrial fibrillation or infection, and generally resolved with standard therapy. Importantly, in an open-label extension FOREST-HCM, where patient judgment guides dose titration and more closely reflects clinical practice, these events have been rare. Leading HCM experts regard these events as manageable in clinical practice, and that gives us confidence in how aficamten can be used in the real world. On the regulatory front, our supplemental NDA based on ACACIA-HCM remains on track for submission to FDA this quarter. As Robert mentioned, we're also preparing to submit to the European Medicines Agency in early 2027. Regarding oHCM, our sNDA supported by MAPLE-HCM is still being reviewed, with a PDUFA date of November 14; we keep working with FDA in a constructive manner and anticipate its decision. All of this progress together strengthens our confidence in what aficamten could achieve as the first cardiac myosin inhibitor to address the complete HCM spectrum. With MYQORZO now available for adults who have symptomatic oHCM, and with ACACIA-HCM backing a possible expansion into nHCM, we perceive a considerable opportunity to serve a wider patient population across the U.S. and globally; and on that note, I'll pass things to Steve.

Stephen Heitner

executive
#5

Thanks, Fady. Our clinical development programs made substantial headway on multiple fronts in Q3. Starting with aficamten, we continue to build on the evidence base behind it. A real-world study called ASPEN-HCM, which examines MYQORZO in obstructive HCM, recently began. We believe these findings will sharpen our understanding of MYQORZO's real-world safety, clinical effectiveness, and impact on health care resources when used in routine practice, and they'll help shape the discussions we have coming up with regulators, particularly around the REMS. In addition, we completed enrollment in the adolescent cohort of CEDAR-HCM, a Phase III trial evaluating aficamten's efficacy, pharmacokinetics, and safety in pediatric patients who have symptomatic obstructive hypertrophic cardiomyopathy, with top line results anticipated in early 2027. Also, our partner Bayer has wrapped up the primary treatment phase of CAMELLIA-HCM — that's the Phase III trial of aficamten in Japanese individuals with obstructive HCM — and the Japan cohort of ACACIA-HCM was completed not long ago. Beyond aficamten, we continue to move our late-stage cardiovascular pipeline forward. With omecamtiv mecarbil, enrollment continued in COMET-HCM, our confirmatory Phase III clinical trial involving patients who have heart failure with severely reduced ejection fraction. Now that every site is active, enrollment has accelerated as anticipated, and we expect that to carry on through 2027. Despite standard of care, these patients are still underserved, with a re-hospitalization rate of roughly 35% within one year. During GALACTIC-HF, omecamtiv mecarbil produced its strongest benefit in individuals with the lowest ejection fractions, and COMET-HF was built to specifically recruit that exact group. Based on baseline characteristics gathered to date, we appear to be matching the intended patient population. That makes us confident about this trial and about the chance to meet a substantial unmet need using omecamtiv mecarbil. Turning to ulacamten, recruitment continued in Cohort 1 of AMBER-HFpEF, our Phase II trial involving people who have heart failure with preserved ejection fraction. We are still on schedule to finish enrollment during this quarter. Given what this study concentrates on, the data we are producing should help clarify what role a cardiac myosin inhibitor might play in HFpEF. We feel good about how we carried out work on a strong late-stage pipeline, and we're eager about a number of key milestones coming up; on that note, I'll hand things over to Sung.

Sung Lee

executive
#6

Appreciate that, Steve. Turning to revenue first: for Q3, total revenues landed at $47.6 million, compared with $1.9 million in the corresponding quarter of 2025. MYQORZO's net product revenues hit $44.5 million, marking 76% growth over the prior quarter. Within that, U.S. net product revenues were $43.1 million, driven by robust demand. In Europe, net product revenues contributed $1.4 million during the third quarter after the second-quarter launch, and that amount reflected initial inventory build in Germany. Collaboration revenue for Q3 was $3.1 million, against $1.9 million a year earlier in 2025. Moving now to operating expenses: R&D spending for the third quarter totaled $99.3 million, compared with $97.3 million during the same period in 2025. That growth was driven primarily by more clinical trial work as well as costs related to personnel. For SG&A in Q3, we recorded $113.1 million, versus $69.5 million during the same quarter in 2025. The main driver behind this increase was external spending associated with the commercial launch of MYQORZO, together with elevated personnel costs, stock-based compensation included. Cost of goods sold for MYQORZO in Q3 came in as a credit of $0.5 million, mostly reflecting a credit related to drug supply optimization efforts. Collaboration cost of revenues — which largely captures partner costs the company is reimbursed for — totaled $2.7 million in the third quarter, compared with $1.9 million in the same period in 2025. For the third quarter, our net loss came to $190.1 million, equal to $1.37 per share, versus a net loss of $306.2 million, or $2.55 per share, during the same period in 2025. Moving on to the balance sheet: we ended the third quarter with approximately $1.6 billion in cash and investments, down from $1.7 billion at the end of the second quarter of 2026. On financial guidance, we are reaffirming our full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million. Our outlook for stock-based compensation, which is included in our GAAP combined R&D and SG&A expense guidance, remains unchanged at $130 million to $140 million. With that, I'll hand the call back over to Robert.

Robert I. Blum

executive
#7

Thanks, Sung. Before we take questions on the call, I want to point out how much progress we've made this year and what lies ahead. Since MYQORZO's launch, we've established a solid commercial base, with almost 1,100 prescribers in the U.S., an expanding footprint in Europe, and approvals in 4 other regions. ACACIA-HCM turned out to be the first positive Phase III trial in nonobstructive HCM, and we keep moving our later-stage pipeline forward, which we believe will fuel longer-term growth beyond aficamten. Right now our focus is on a strong finish to the year, with a number of important milestones coming up. Next week, we anticipate an FDA decision on MAPLE-HCM. Before the year ends, we intend to file our sNDA covering the ACACIA-HCM results. We expect to launch MYQORZO in the U.K. during this quarter and to finish enrolling Cohort 1 of AMBER-HFpEF. And in early 2027, we expect to submit our application for the ACACIA-HCM results in the EU, launch in further countries in 2027, and also report top line results from the adolescent cohort of CEDAR-HCM. We're doing all of this from a position of financial strength, with a strong balance sheet that backs our launch activities, our pipeline advancement, and our longer-term value creation; we believe we're well positioned to deliver continued growth and to carry out our priorities as guided by Vision 2030; and with that, operator, let's now open the call to questions, please.

Carter Gould

analyst
#8

Great, good afternoon, and thanks. Hi Robert, good afternoon, and thanks for taking my question. Robert and Andrew, I appreciate all those metrics. As I try to reconcile some of the implied sequential growth at the market level with your commentary, it seems to suggest a step-up of roughly 400 to 500 incremental patients at the CMI level quarter-on-quarter. In a way, I'm asking you to bless that math, but also perhaps to comment on whether you think that kind of step-up is sustainable as we look at the quarters ahead? Or are there governors at the site level that might tamp down the ability to step up sequentially?

Robert I. Blum

executive
#9

Sure. Andrew, would you like to comment, please.

Andrew Callos

executive
#10

Okay, Carter. So to your point, yes, sequential growth is happening. Prescriptions are probably closer to around 300. When you include free drug, the figure could rise higher, though I'd say the math works out to slightly more than 3,000 patients in the category, which is roughly 300 above the second quarter. As for sustained growth, definitely, as we said earlier in the call during the remarks, almost 80% of the market remains available. If we keep seeing these prescribers we call naive — meaning they hadn't prescribed a CMI before our launch — and if new prescribers for the category keep growing well, that is certainly what drove most of the growth in Q3, as I mentioned. Our expectation is that this will continue, so you'll keep seeing growth in the category.

Robert I. Blum

executive
#11

Carter, let me add one comment here. What I find particularly encouraging is the source of that growth. It isn't arriving only from the velocity accounts — it's also coming from a wider base of new-to-category prescribing. So we should expect growth to hold sequentially, and at some point that may, hopefully, also turn into higher velocity growth.

Tessa Romero

analyst
#12

Hi Robert and team. Are you going to give longer-term guidance on MYQORZO at our small conference in January? Or will that be something further out for Cytokinetics? And then just to follow up on what Carter asked, Andrew, is north of 3,000 adds the right way to think about the run rate for this category?

Robert I. Blum

executive
#13

So on your first question, I'll say we're still discussing how we'll approach 2027 and what we'll speak to in terms of guidance. And certainly, over the longer term, you can expect that we'll speak to where we see this ultimately going for the company's benefit. But it's premature, I think, to comment on that today. Andrew, do you want to address the comment about 3,000?

Andrew Callos

executive
#14

Okay, so when you take the year-to-date figures and include an assumption for free drug, our estimate for the category comes to roughly 9,000 patients through the close of the third quarter. That growth is baked in. So yes, I definitely believe 3,000 or more each quarter going forward is achievable; and clearly, once nHCM joins the picture, the HCM categories ought to expand by even more than that.

Robert I. Blum

executive
#15

If you look at where we stood 12 months back, the category has grown considerably compared with the prior year.

Tessa Romero

analyst
#16

Thanks, Robert.

Akash Tewari

analyst
#17

Hi, thank you very much; I was wondering whether you might comment on Edgewise putting forward something like a Phase III design that doesn't use echo-guided dose adjustments — more of a symptomatic paradigm, so to speak. To what extent have you talked with the FDA about bettering the REMS that accompanies your titration with MYQORZO? Might we move toward a symptomatic paradigm for your drug? As I recall, only about 1.3% of your patients actually had a titration change mandated by LVEF during SEQUOIA. So it appears at least feasible to do that; and what long-term data would you need to submit to the FDA in order to get that done?

Robert I. Blum

executive
#18

So prior to handing things over to Fady, let me just say the following. Nothing that any fast follower is considering is something we here at Cytokinetics haven't already been discussing for quite a while. And we do think it will fall to us, using real-world evidence, to show where we can get with a potentially relaxed or even removed REMS over time; but that does require — based on our intuitions and our communications with regulatory authorities — some real-world evidence, which will come with what will ultimately be thousands of patients, but certainly within line of sight to what we expect we can accomplish here over a period of time. I'll ask Fady to comment on where these potential strategies could take us.

Fady Malik

executive
#19

Thanks, Robert. I think the main point is that we clearly have a chance to streamline the titration protocol, and there are measures we can take. I won't go into details at this moment about things that would permit more adaptable use of echoes while titrating or alternative beginning doses, that sort of thing. I agree with Robert's strong argument that any freshly launched drug likely won't come with a safety profile built on a few hundred patients who were treated for a couple of dozen weeks. Basically, the FDA clearly is looking for real-world evidence covering thousands of patients who’ve been on treatment for many months, or even years. That said, my expectation is that within two to three years—as data emerge from the REMS and from what we’re learning through real-world evidence—we’ll be able to further confirm the safety profile we’ve already seen for aficamten and open up approaches for streamlining the REMS. I’d also note that our real-world experience so far indicates that the majority of patients reach the maintenance phase while on either 5 or 10 milligrams of aficamten. That tells us patients find those doses effective at easing their symptoms. How they bring together symptom evaluation, biomarkers, and LVOT assessments is up to them to decide—and honestly, whether dose titration needs simplifying may end up being a moot point if patients are doing well at the initial dose or after one adjustment.

Robert I. Blum

executive
#20

To emphasize this point, Cytokinetics holds a firm conviction regarding the trustworthiness and honesty of the way we handle these issues. We also think the optimal route to reaching those results — which include easing or eliminating the REMS — is to keep doing exactly what we have been doing all along: breaking new ground and taking the lead here. That connects to what real-world evidence will deliver, since a plan is already in position.

Cory Kasimov

analyst
#21

Hi, Josh here, filling in for Cory. Could you help us get a sense of how big the EU opportunity is compared with the U.S.? And when would you expect a meaningful step up there?

Robert I. Blum

executive
#22

Sure. I'll ask both Andrew and Sung to address that, beginning with Andrew, please?

Andrew Callos

executive
#23

Absolutely, and thanks for asking. As I said, we've now launched in Germany — that's the biggest market. On the whole, once both Europe and the U.S. are mature, we expect Europe to account for roughly 15% of revenue. Things do tend to move a bit more slowly in Europe. In Germany, you're able to launch at approval while price negotiations are underway. In the other large markets, though, you need to — once regulatory approval comes through, you have to file with a health technology assessment body to secure reimbursement, and that typically takes, let's say, 12 to 18 months following approval. So the more meaningful revenue will likely show up around the 2028 to 2029 period. With that, I'll hand things over to Sung in case he has anything to add.

Sung Lee

executive
#24

Yes, Josh, I'll just add a quick point. If you look at Europe, this isn't specific to us — it's true throughout the industry — launches there tend to be lengthy and gradual and steady, correct, particularly when you go through the HTA process country by country, where launches are staggered. So I think that has to be kept in perspective; ultimately, this is a long game for us, and we do expect meaningful contributions from Europe. As Andrew mentioned, that could be 15% of our total MYQORZO net product sales.

Analyst

analyst
#25

Thanks.

Maxwell Skor

analyst
#26

Great, thanks so much for taking my question. Could you go into a little more detail on the profile of patients with nHCM who might be eligible? For instance, what proportion of those diagnosed would satisfy ACACIA's entry criteria? And is that roughly the correct starting point when it comes to sizing the market?

Robert I. Blum

executive
#27

I'll turn to Steve to address that, please.

Stephen Heitner

executive
#28

The way ACACIA was set up, the criteria we used basically identify patients who have symptomatic nonobstructive HCM. And what we showed at the ESC — especially that forest plot — was no heterogeneity in treatment effect across the prespecified subgroups we examined, so age, sex, whether patients had a particular ejection fraction, or preexisting atrial fibrillation, none of those appeared to have an impact. If we get regulatory approval, the way we'd envision this being implemented is that patients would come in, and if they have any symptoms plus a diagnosis of nonobstructive HCM and an ejection fraction above 55% or 60%, those patients would qualify for a treatment trial, at least with aficamten.

Maxwell Skor

analyst
#29

Great, thanks.

Salim Syed

analyst
#30

Congrats on the progress, guys. We've got one question on omecamtiv mecarbil. So in the commentary on the call, you said enrollment has been accelerated, but the press release now lists continuing enrollment through 2027, if I'm not mistaken, versus through 2026 in the 2Q. So I'm just wondering if you could square those dynamics for me. What exactly is happening with enrollment that led you to change the language on when you expect enrollment to go through in 2027 versus 2026?

Robert I. Blum

executive
#31

Sure. I'm going to ask Fady to comment on that, please.

Fady Malik

executive
#32

Earlier releases only described what was occurring in 2026. When you go through the milestones we laid out, the wording essentially covers what we plan for 2026, and enrollment was going to keep going through 2027 rather than through 2026. We never anticipated enrollment finishing in 2026. If we had, that would have been stated in the guidance. Clearly, enrollment is not going to wrap up in 2026. It will wrap up at some point in 2027. And we will provide guidance on that point when we provide guidance covering the remainder of 2027.

Salim Syed

analyst
#33

All right. Understood. Thank you very much.

Roanna Ruiz

analyst
#34

Hi everybody. Good afternoon. I had a question about the naive prescribers of MYQORZO. Do they tend to be found more at community hospitals instead of big academic centers, or is it more of a blend? And when it comes to achieving deeper penetration among that group, what's your thinking on building breadth and depth and perhaps turning some of them into high-volume prescribers?

Robert I. Blum

executive
#35

Andrew, would you handle that, please?

Andrew Callos

executive
#36

Okay, and thank you for that question. Yes, the great majority of them are community cardiologists, and the prescribing depth among those doctors at present is generally 1 to 2 scripts that we observe with each of them. I think, first, they see fewer patients than the academic centers do. So we don't anticipate that same degree of demand being driven. But as they gain more experience — and what we're finding is that once a physician has treated 3 or 4 patients, they've gained experience with the REM, they've gained experience with MYQORZO, they have experience with market access — they usually then come on board. But it does require a bit of time, and we do expect prescribing depth within that group along with continued expansion. One of the points I raised regarding nHCM: on average, you're effectively doubling the patient population for each of those prescribers should nHCM be approved. And there's certainly the ability to leverage oHCM and nHCM as a sort of dual indication, which gives you even more opportunity for that experience to build depth.

Roanna Ruiz

analyst
#37

Understood. Appreciate it.

Andrew Callos

executive
#38

Absolutely. Thanks for asking.

Eric Joseph

analyst
#39

Good evening, and thank you for taking the questions. Based on your conversations with the cardiology community about the full ACACIA data, could you speak a little about the feedback you may have gotten concerning the titration scheme used in the study? I'm just wondering, as you head toward your planned sNDA submission, whether you might propose a scheme that differs somewhat from the protocol, one focused more on positive symptoms or symptom improvement rather than safety-driven stopping rules?

Robert I. Blum

executive
#40

Sure. As you know, we're looking at the data from both ACACIA-HCM and FOREST-HCM, and I'll ask Fady and Steve to comment, please.

Fady Malik

executive
#41

So, as Robert sort of mentioned, if you recall how we handle the titration schedule for obstructive HCM, we drew on data from the randomized clinical trial SEQUOIA and supplemented it with what we learned from FOREST-HCM; that forms part of the plan we're putting into place for the sNDA for nonobstructive cohorts. The input we've received up to now—and it's beyond just input, it's evidence that has been produced. And in fact, we presented this at the investor meeting we held following the presentation, regarding the data in Munich, which was that carrying out the dosing schedule designed in FOREST seemed easier, first of all, for physicians and patients given the flexibility, and was also linked to fewer adverse events observed in the clinical trial; so I think what we're hearing is, please, can we make every effort to get that kind of titration regimen into the real world, which would also line up well with what already exists in the real world for obstructive HCM. I hope that addresses your question.

Eric Joseph

analyst
#42

That was excellent. Appreciate you fitting us in. Congratulations on a solid quarter.

Ashwani Verma

analyst
#43

Great. Yeah, thank you for the question; so I suppose I just wanted to hear your thinking on the competitive claims here that lacking an echo monitoring requirement while titrating could confer a meaningful edge in oHCM. And it appears Edgewise has discussed this openly, having proposed one baseline echo plus one at end of study. Just curious about your view on whether that could actually shift in a favorable way once we see the finalized Phase 3 trial design in the near term.

Robert I. Blum

executive
#44

So I'd rather not devote too much time to speculation about a different company's development program; but what I will say is that FDA can allow you to do just about anything in a clinical trial; and in the end, it will be after data become available and upon review of an NDA that the FDA may weigh what it ultimately wants to see in a potential approval and labeling. We've seen that happen to us directly. As you may recall, in SEQUOIA-HCM, we observed no dose terminations tied to EF excursions and one would not have imagined it necessary to even have such regulatory restrictions on dose titration and echos given those data, except that FDA upon review judged it prudent, until such time as it had real-world evidence, to put the REMS requirements in place that we complied with, and that's what we have now for MYQORZO. I might ask Fady to comment on, during a regulatory review, who actually gets involved in making these decisions, because it may not always be obvious to those listening on this call.

Fady Malik

executive
#45

Yes. When we evaluate these matters, multiple FDA divisions are involved—not only the cardiorenal division, which typically handles protocol review along with the efficacy and safety of clinical trials. The division of risk management also participates when the question is whether REMS are needed or not, and their perspective can differ considerably from cardiology's; in fact, our publicly released documents concerning aficamten's approval show exactly that kind of exchange between the division and the division of risk management. So it's difficult to predict what a protocol will reveal and how that eventually translates into whether there is a REMS or not, or what its structure would be; and I believe we should probably hold off on that discussion until we have data.

Robert I. Blum

executive
#46

Yes. I might ask Steve also to weigh in here.

Stephen Heitner

executive
#47

From a clinician's standpoint, I'd like to add something here. It isn't as though echoes are inherently a burden or that they aren't warranted for these patients. The truth is, when it comes to obstructive HCM, cardiologists will tell you that the echo is exactly the tool they reach for when judging how well any given treatment is working. So assuming that a patient with obstructive HCM will simply never have another echo done strikes me as presumptuous. What matters is flexibility — being able to decide when an echo is needed, and in the end, how many of them a given patient will need. As Fady mentioned earlier, what we observe in the clinic is that a lot of patients visit their providers and come out of the titration phase with only 5 or 10 milligrams proving sufficient. That's what happens in the real world. It mirrors what was observed in the EXPLORER-HCM clinical trial and what later played out with CAMZYOS in real-world practice, where lower doses turned out to be the dose patients ultimately required. So one could picture that in today's setting, patients on MYQORZO need merely 1 or 2 echoes each year. That's a tough standard to beat, particularly when you factor in that those echos are already flexible in what they require under the REMS program we have in place.

Robert I. Blum

executive
#48

That should be useful. To put it briefly, we do think—once again, as a pioneer and leader in this area—that by leveraging real-world evidence, we are well positioned to keep being the innovator here, including when it comes to how often echoes are performed.

Jim Condulis

analyst
#49

This is Mark calling in for James. Just a quick question from our side about the nHCM launch: do you figure the kinetics, or the cadence, of the nHCM rollout will mirror the obstructive launch? In other words, is oHCM the right analog for how we ought to be thinking about overall nHCM uptake or trajectory? And more broadly, do you expect anything regarding REMS or monitoring to change once the label expansion happens?

Robert I. Blum

executive
#50

Before I hand things to Andrew, let me just emphasize that, if approved in nHCM, MYQORZO would be the first and only. And in that respect, some education, awareness, market development and other activities need to take place even though we'll be building on the base of an already strong business and launch momentum in oHCM. But then, Andrew, would you like to add anything to that?

Andrew Callos

executive
#51

Absolutely. We’ve really given this quite a lot of thought and looked into it. What I’d say the main takeaway is: we do anticipate quicker adoption among current MYQORZO prescribers, since they know MYQORZO, have used it, understand the REMS, and are already familiar with the dosing and echo requirements. So we expect faster uptake within a subset—specifically, those who are fairly experienced CMI users.

Robert I. Blum

executive
#52

On the REMS question as well, perhaps I can turn it over to Fady to speak to what our approach might look like for REMS in connection with the sNDA in nHCM.

Fady Malik

executive
#53

Okay. What you track in nHCM is identical to what you track in oHCM. And once patients entered FOREST, they basically adhere to the same schedule and the same thresholds for deciding whether to down titrate or whether they must interrupt the drug, and so on. So our hope is that there would be very few modifications to how the REMS is implemented at present. But naturally, that is going to call for some talks and negotiation with FDA.

Analyst

analyst
#54

Thanks.

Alex Xenakis

analyst
#55

Hello, and thanks for taking our questions. Alex here, speaking on behalf of Kripa. Ahead of next year's launches in the extra ex-U.S. markets, we'd like to know whether you can share any color on the discussions you've had with prescribers. Also, how would you characterize physician appetite for MYQORZO compared with how much further physician education might be required to drive growth in that market?

Robert I. Blum

executive
#56

Is your question specifically about Europe?

Alex Xenakis

analyst
#57

Yes, that's specifically about Europe.

Robert I. Blum

executive
#58

All right. Andrew, would you like to handle that, given that we're moving toward launches one country at a time in sequence?

Andrew Callos

executive
#59

Sure. So in every major European country, we've now filed all of our dossiers. As we've said, we expect to launch across every major market. The major markets got more of our attention — think Italy, Spain, France, the U.K., Germany — though we've definitely also devoted time to the Western European markets. We have teams set up in Europe, field-based medical colleagues, our general management teams, our marketing teams, and we've completed market research. So we expect uptake along the lines of what Germany is showing. In Germany, at 5 or 6 months, new-to-brand products are market leaders and performing very well. You also need to keep in mind that in Europe there's no REMS program tied to launch. There's no patient support. Once payer access is secured, access generally isn't much of a hurdle. That's the reason you negotiate. So the launch happens country by country. The price is lower, but we anticipate solid uptake, and our research shows physicians perceiving a clear differentiator, just as we're seeing in Germany.

Alex Xenakis

analyst
#60

Appreciate the extra detail.

Alethia Young

analyst
#61

Congratulations on everything achieved with MYQORZO. I’d like to explore a bit further how — as we consider the scale of the opportunity, how wide it might be, perhaps during the second half of the year, the value of possible first-line use and having that label. Could you speak a little about how you expect that will shape things for physicians and then, in the end, reach a broader label potentially nonobstructive. I mean, do you believe that is roughly what physicians want as an all-in-one answer, maybe?

Robert I. Blum

executive
#62

Yes. Andrew is able to speak to some of the market research he has conducted in and around this area and what adding nHCM might mean both across o and nHCM. Andrew, please?

Andrew Callos

executive
#63

Okay, so when you mention the second half, do you mean the fourth quarter, or are you asking about next year? I just want to be sure I understand your question correctly.

Alethia Young

analyst
#64

Turning to nonobstructive, next year the first line will come in the fourth quarter.

Andrew Callos

executive
#65

Got it. Okay, so regarding nonobstructive, like I said, the overall market is the same size as oHCM, though clearly there are 2 players in that market today; if we get approved for nonobstructive, we'd be the first and only. And based on our research, yes, particularly in the community, physicians want more of a one-stop shop. They mentioned faster uptake. They mentioned having experience, and with a dual indication — both o and n — driving share. On the MAPLE side, we aren't pursuing a monotherapy or a first-line therapy. What we're really trying to do is generate evidence from what's in the guidelines today — which most community cardiologists regard as metoprolol, that specific beta blocker, having truly been the standard of care — and show them the difference in the data, as well as educate patients who take metoprolol that there may be something better, assuming we get that in the label and everything this year. So I think both of those will provide a lift. Obviously, nHCM is a much broader lift in terms of revenue opportunity. MAPLE really just extends our differentiation, and I think it gives us some good data to educate community cardiologists with. Thanks for the question.

Alethia Young

analyst
#66

Thank you.

Yasmeen Rahimi

analyst
#67

Hi team. Thanks a lot for all of the updates. Perhaps I'd really like to get a sense of, with MAPLE now coming onto the label, how quickly that could actually shift how payers view removing the requirement that patients be on a beta blocker and making MYQORZO the first choice, and as a result, whether it could grow the potential TAM of patients and uptake; we appreciate your perspective.

Robert I. Blum

executive
#68

Sure. So certainly, we hope the MAPLE data will be reflected in an expanded label, and that is one step toward the objective you mentioned. But payers may have their own agenda. And I'll ask Andrew to comment on what may factor into payer decisions, including what ultimately may be enabled by changes in guidelines.

Andrew Callos

executive
#69

Sure. We aren't counting on first line, and we aren't chasing it either. There will be a role for beta blockers. From a payer perspective, every prior auth criterion I know of calls for beta blocker use, or prior use of a beta blocker; we have no plans to alter that. What we actually want is faster uptake of MYQORZO, and we want to help get guidelines informed. That, I believe, will carry more weight with community cardiology and possibly with payers as time goes on; but it mainly strengthens the evidence base. It mainly strengthens the case for a community cardiologist to grasp more clearly how the CMI is used relative to something they have done for many years. It helps get guidelines informed, and that in turn generates greater demand. And from a MAPLE standpoint, that is genuinely what we are pursuing. MAPLE additionally lets us talk with patients — something we don't do at present — about what they may be taking as a beta blocker right now and that something better might exist for them; so those are the sorts of things we consider strategically from a commercial standpoint, though treating first-line therapy as a target is likely not realistic over the coming couple of years.

Robert I. Blum

executive
#70

Of course you still have a meaningful voice in this conversation, but what that might translate into is faster step edit times through beta blockers, which is perhaps more practical in the near term.

Josh Brewer

analyst
#71

This is Joshua, calling in for Leo Timashev. I was hoping you could help us frame what to expect from the HFpEF data for ulacamten in '27. Also, how are you planning to share those results across the different cohorts?

Robert I. Blum

executive
#72

Sure. As you can appreciate, ulacamten in HFpEF is still at an early stage of the development program, and in this first Phase II study we're quite eager to learn what things could look like from a PK and PD perspective. I might hand things over to Fady to discuss Cohort 1 and what we may be communicating.

Fady Malik

executive
#73

Yes. I believe that during 2027, we'll have results available from Cohort 1. That cohort essentially serves as a dose-finding effort, focused on learning about safety and tolerability. So whatever comes out of it might simply be described in summary form on one of our calls when we walk through progress. In the end, we always aim to make such data publicly available, though no particular schedule or plan for doing so exists at this point.

Yanan Zhu

analyst
#74

On the oHCM launch — you're nearing that 50% target for new-to-brand share by year-end. I'm curious, as we look toward 2027, are there any expectations for that metric? And is there any reason it couldn't rise substantially further? That covers the new-to-brand side. On switching, could you share any color on what percentage of prescriptions this quarter involve switching patients?

Robert I. Blum

executive
#75

Sure. I'll begin and then hand it to Andrew. Clearly, the statement we made earlier this year was already quite bold — committing to a goal of north of 50% new-to-brand share while also seeing such significant category growth. Andrew, would you like to comment on what our objectives may be from this point forward?

Andrew Callos

executive
#76

Absolutely. So we're highly focused on that new-to-brand share being above 50%. I'd say that's a solid leading indicator. When you break it down by segment, our share among the highest writers — the velocity accounts, as we call them, which historically made up 80% of the business — we're already quite near 50% with that group, so given that this represents most of the volume, I think that's a good leading indicator. So as we look toward 2027, I think what we'll really be doing is establishing a firmer foothold, taking that 50 and pushing it past 50. At the same time, that broader prescriber base, using MAPLE ahead of ACACIA arriving — assuming ACACIA is approved — that's really where our focus will be. We'll concentrate on continuing to grow share within those core velocity accounts while widening the markets to those naive prescribers — those who've begun prescribing with greater depth, and those who haven't, using MAPLE and using SEQUOIA to begin gaining experience. And then, assuming ACACIA comes aboard, as I said earlier, that roughly doubles the patient base for each of these groups, and we'll keep looking to grow prescribing there. So that's really roughly how we're approaching 2027, on top of the successful launch we've had so far.

Yanan Zhu

analyst
#77

Do you have anything to say about switching?

Andrew Callos

executive
#78

Switching — right, sorry. Yeah, switching sits at mid-single digit. So it isn't a big factor for us. We don't promote it. We don't talk about it; that's really a matter between a physician and a patient; and for us it's not a major driver. Once again, a mid-single-digit percentage of our total patients arrived via switches.

Robert I. Blum

executive
#79

Yes. As for expanding the category, expect additional publications involving more patients over a longer period in the open-label extension trial, FOREST. And when it comes to switching, an investigator-initiated study is currently running that could shed light on switching later on.

Yanan Zhu

analyst
#80

All right. Appreciate the additional detail.

Jason Zemansky

analyst
#81

Congratulations on a solid quarter. Let me try to tie a few things together. You put category growth at 3,000 new patients quarter-to-date. I suppose my question is, what do you view as the biggest obstacle to widening the patient funnel ahead of nHCM? Is it mostly about growing the prescriber base? Is it access? Is it patient activation? And when might we see the run rate inflect? Is that a 2027 event? Or is nHCM the true catalyst?

Robert I. Blum

executive
#82

Sure. So we're 4 years into this category. As you know, CAMZYOS came before us, and now with MYQORZO in this market, it's a fair question when we might see an exponential inflection in that growth. So Andrew, would you like to comment on those points?

Andrew Callos

executive
#83

Sure. So on uptake, I really don’t see anything standing in the way at launch. There’s a solid prescriber base in place now. In the CMI category, there are several thousand prescribers. We’re above 1,000 prescribers and still growing. Quarter to quarter, we add roughly 400. I think those groups, especially the centers of excellence—what we call these velocity accounts—have been telling us they are sort of “warehousing patients,” and they have patients in mind. So I think you’ll see several months of growth come from that group. When you think about an inflection point, that inflection point is really going to be driven by this prescriber base. I think we said this even before launch: historically, there were 700 physicians who made up 80% of the market, and you’re not going to reach a multibillion-dollar market because that few physicians can’t treat enough patients to get to those revenue levels. So as a category, we really need to keep expanding those prescribers. ACACIA, again, as I mentioned, doubled their patient population. So I don’t want to put a date on it, but I think that is the inflection point—where you get enough of these expanded prescribers who have 3 or 4 patient seats, they’ve gained enough experience, and they’re now at the point where they feel comfortable having that conversation sooner with the patient, and having that conversation and getting and treating themselves as compared to referring; referring slows things down as well. So I think we’ll do more work on when we see a change in the inflection point. But as Robert mentioned, the category has been on the market for 4-plus years. And as cardiology launches often go for several years, it’s been linear, but I do think we will see an inflection point. Hopefully, that answers your question.

Robert I. Blum

executive
#84

And to add to what you asked about headwinds and obstacles: we've traveled quite a distance from the kinds of discussions we used to have on these calls about REMS and differentiated REMS, and whether that alone would be a big obstacle. What we're already seeing, just in these fairly few quarters since MYQORZO became available, is a substantial broadening of the prescriber base — both those who prescribed at low volume and those who had never prescribed at all. And I really believe that highlights how our positioning in this category has fueled category growth and a shift toward what could be a preferential share of new scripts. So that's very encouraging to us, and hopefully it keeps going.

Amine Chaherli

analyst
#85

Nice work on the quarter; Amine here, sitting in for Mayank Mamtani. I've got a question for Fady. In ACACIA, the strongest effect showed up among patients with, I suppose, elevated NT-proBNP and preserved filling pressure physiology. You also provided some concrete figures on the diastolic side. So how has that shaped patient selection and dosing in AMBER-HFpEF? And now that Cohort 1 has finished enrolling this quarter, what would you need to see to advance ulacamten into a pivotal trial?

Fady Malik

executive
#86

Yes. When I look at the forest plot for ACACIA-HCM, I wouldn't describe any factor as a strong driver. I need to go back and check the NT-pro difference specifically, but I don't believe it's perhaps as strong as you're suggesting. Naturally, we understand that elevated NT-proBNPs generally mean higher filling pressures and greater left atrial size. Cardiac myosin inhibitors positively affect those measures in nHCM and definitely shape our patient selection for a study such as AMBER; so we've included NT-proBNP criteria in AMBER that we have < >. So I believe determining the appropriate patient population in HFpEF is among our objectives. And the Cohort 1 data may point us in the same direction or a different one. We'll adapt as we start to zero in on where we think the MoA could be helpful. But it is a competitive advantage, as we consider how best to design a study in HFpEF, that we have the benefit of the ACACIA results given where the lines are blurred in some respects between some of the patients who have an nHCM and where we're pointing with ulacamten in HFpEF.

Serge Belanger

analyst
#87

Good evening. This may be one for Andrew. I might have missed it during your prepared remarks, but could you speak to the amount of switching from CAMZYOS to MYQORZO you observed this quarter — was it steady, and does it explain the decline BMS reported in CAMZYOS sales for the third quarter in the U.S. last week?

Andrew Callos

executive
#88

Sure. Switching didn't play a major role in overall growth. It's in the mid-single digits. So out of roughly every 1,000 patients, we might see something like 40, 50, 60 switches, in that range. So that's not a large number, and it isn't something we're pursuing strategically. We're not messaging it fully between a physician and a doctor. Obviously, I can't comment on BMS' earnings.

Robert I. Blum

executive
#89

Thanks, operator. And I really appreciate everyone joining us on the call today. We're grateful for your ongoing backing and for the interest you take in what we're doing. Clearly, we have strong feelings about Q3 being a good quarter, and we're encouraged about where that leads us going forward. Operator, with that said, we can wrap up the call now.

Operator

operator
#90

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.